What is DAMORA THERAPEUT's earnings per share (EPS)?

DAMORA THERAPEUT (DMRA) reported diluted earnings per share of $3.98 for fiscal year 2025. This represents a 121.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

DAMORA THERAPEUT Financials

DMRA

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows DAMORA THERAPEUT (DMRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of DAMORA THERAPEUT's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

DAMORA THERAPEUT carries a low D/E ratio of 0.08, meaning only $0.08 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 12.98, DAMORA THERAPEUT holds $12.98 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

DAMORA THERAPEUT generates a -87.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -135.4% the prior year.

Piotroski F-Score Weak

2/9

DAMORA THERAPEUT passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.03x

For every $1 of reported earnings, DAMORA THERAPEUT generates $0.03 in operating cash flow (-$6.7M OCF vs -$209.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-180.7x

DAMORA THERAPEUT earns $-180.7 in operating income for every $1 of interest expense (-$210.9M vs $1.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$210.8M

YoY-848.1%

DAMORA THERAPEUT's EBITDA was -$210.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 848.1% from the prior year.

Net Income

-$209.8M

YoY-878.8%

DAMORA THERAPEUT reported -$209.8M in net income in fiscal year 2025. This represents a decrease of 878.8% from the prior year.

EPS (Diluted)

$3.98

YoY+121.5%

DAMORA THERAPEUT earned $3.98 per diluted share (EPS) in fiscal year 2025. This represents an increase of 121.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$257.6M

YoY+1717.5%

5Y CAGR+9.5%

DAMORA THERAPEUT held $257.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.00

DAMORA THERAPEUT paid $0.00 per share in dividends in fiscal year 2025.

Shares Outstanding

YoY+21.3%

DAMORA THERAPEUT had 2M shares outstanding in fiscal year 2025. This represents an increase of 21.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-87.3%

YoY+48.1pp

5Y CAGR-66.2pp

DAMORA THERAPEUT's ROE was -87.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 48.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$26.9M

YoY+320.1%

5Y CAGR+1.8%

DAMORA THERAPEUT invested $26.9M in research and development in fiscal year 2025. This represents an increase of 320.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

DMRA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$26.9M+320.1%	$6.4M-73.1%	$23.8M-50.7%	$48.2M+25.2%	$38.5M+56.3%	$24.6M
SG&A Expenses	$9.7M-7.8%	$10.5M-17.2%	$12.7M-2.4%	$13.0M-5.4%	$13.7M+52.5%	$9.0M
Operating Income	-$210.9M-847.3%	-$22.3M+44.2%	-$39.9M+34.8%	-$61.2M-17.2%	-$52.2M-55.3%	-$33.6M
Interest Expense	$1.2M+38.3%	$844K-50.0%	$1.7M+133.9%	$722K+362.8%	$156K	N/A
Income Tax	$50K+22.0%	$41K	$0	$0	$0	$0
Net Income	-$209.8M-878.8%	-$21.4M+44.1%	-$38.3M+37.8%	-$61.6M-19.1%	-$51.8M-48.6%	-$34.8M
EPS (Diluted)	$3.98+121.5%	$-18.53+48.6%	$-36.08	$-2.43-18.5%	$-2.05	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$1.4M-3.3%	$1.5M+116.1%	$678K	N/A	$1.1M-40.4%	$1.8M-25.5%	$2.5M
SG&A Expenses	N/A	$1.7M-11.0%	$2.0M+1.8%	$1.9M	N/A	$2.7M-1.0%	$2.8M-15.3%	$3.3M
Operating Income	N/A	-$3.2M+7.7%	-$3.4M-31.6%	-$2.6M	N/A	-$3.8M+31.1%	-$5.6M+2.9%	-$5.7M
Interest Expense	N/A	$42K-16.0%	$50K-32.4%	$74K	N/A	$146K-31.5%	$213K-17.1%	$257K
Income Tax	N/A	$0-100.0%	$4K+100.0%	$2K	N/A	$7K-83.3%	$42K	N/A
Net Income	N/A	-$3.1M+8.8%	-$3.4M-35.7%	-$2.5M	N/A	-$3.9M+27.3%	-$5.3M+2.5%	-$5.5M
EPS (Diluted)	N/A	$-2.36+9.2%	$-2.60-35.4%	$-1.92	N/A	$-3.39	$-4.92+2.6%	$-5.05

DMRA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$260.5M+1420.7%	$17.1M-55.2%	$38.2M-47.8%	$73.2M-40.1%	$122.2M-28.8%	$171.6M
Current Assets	$260.4M+1446.5%	$16.8M-54.2%	$36.8M-42.5%	$63.9M-42.0%	$110.1M-35.0%	$169.3M
Cash & Equivalents	$257.6M+1717.5%	$14.2M-34.0%	$21.5M-34.5%	$32.8M-47.6%	$62.6M-61.8%	$163.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$20.1M+1448.6%	$1.3M-77.9%	$5.9M-48.4%	$11.4M+129.1%	$5.0M-18.3%	$6.1M
Current Liabilities	$20.1M+1576.4%	$1.2M-79.5%	$5.8M-47.5%	$11.1M+144.4%	$4.5M-18.4%	$5.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$240.4M+1418.4%	$15.8M-51.0%	$32.3M-47.6%	$61.8M-47.3%	$117.2M-29.2%	$165.5M
Retained Earnings	-$487.4M-75.6%	-$277.5M-8.4%	-$256.1M-17.6%	-$217.7M-39.5%	-$156.1M-49.6%	-$104.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$260.5M+2326.7%	$10.7M-21.6%	$13.7M-10.9%	$15.4M-10.3%	$17.1M-26.7%	$23.4M-14.4%	$27.3M-15.9%	$32.5M
Current Assets	$260.4M+2561.2%	$9.8M-24.9%	$13.0M-12.7%	$14.9M-11.4%	$16.8M-20.5%	$21.2M-15.9%	$25.2M-17.6%	$30.5M
Cash & Equivalents	$257.6M+3287.1%	$7.6M-25.5%	$10.2M-14.5%	$11.9M-15.8%	$14.2M-28.0%	$19.7M-13.9%	$22.9M+8.4%	$21.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$20.1M+638.3%	$2.7M-0.3%	$2.7M+65.3%	$1.7M+27.3%	$1.3M-46.7%	$2.4M-34.2%	$3.7M-14.1%	$4.3M
Current Liabilities	$20.1M+665.0%	$2.6M-0.2%	$2.6M+69.5%	$1.6M+29.6%	$1.2M-51.0%	$2.4M-34.2%	$3.7M-14.1%	$4.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$240.4M+2902.1%	$8.0M-26.9%	$11.0M-20.1%	$13.7M-13.4%	$15.8M-24.4%	$20.9M-11.2%	$23.6M-16.2%	$28.2M
Retained Earnings	-$487.4M-70.0%	-$286.6M-1.1%	-$283.5M-1.2%	-$280.1M-0.9%	-$277.5M-2.5%	-$270.8M-1.5%	-$266.9M-2.0%	-$261.6M

DMRA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$6.7M+63.9%	-$18.6M+49.5%	-$36.9M+14.0%	-$42.9M+17.9%	-$52.3M-36.9%	-$38.2M
Capital Expenditures	N/A	N/A	N/A	$196K-12.1%	$223K	N/A
Free Cash Flow	N/A	N/A	N/A	-$43.1M+17.9%	-$52.5M	N/A
Investing Cash Flow	-$17.4M-249.1%	$11.7M-47.8%	$22.3M+80.3%	$12.4M+125.8%	-$48.0M	N/A
Financing Cash Flow	$266.8M	N/A	$2.9M+467.3%	$507K	N/A	$187.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$566K+121.6%	-$2.6M-16.9%	-$2.2M+8.3%	-$2.4M+50.6%	-$4.9M-35.2%	-$3.7M+11.0%	-$4.1M+30.9%	-$5.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	$0	$0-100.0%	$6.0M+6.2%	$5.7M
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

DMRA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-87.3%+48.1pp	-135.4%-16.8pp	-118.6%-18.8pp	-99.8%-55.6pp	-44.1%-23.1pp	-21.1%
Return on Assets	-80.5%+44.6pp	-125.1%-24.8pp	-100.3%-16.1pp	-84.2%-41.9pp	-42.4%-22.0pp	-20.3%
Current Ratio	12.98-1.1	14.07+7.8	6.31+0.6	5.75-18.5	24.23-6.2	30.42
Debt-to-Equity	0.080.0	0.08-0.1	0.180.0	0.19+0.1	0.040.0	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-39.1%-7.7pp	-31.4%-12.9pp	-18.5%	N/A	-18.6%+4.1pp	-22.6%-3.2pp	-19.4%
Return on Assets	N/A	-29.2%-4.1pp	-25.1%-8.6pp	-16.5%	N/A	-16.6%+2.9pp	-19.6%-2.7pp	-16.9%
Current Ratio	12.98+9.2	3.73-1.2	4.96-4.7	9.62-4.4	14.07+5.4	8.68+1.9	6.79-0.3	7.07
Debt-to-Equity	0.08-0.3	0.34+0.1	0.25+0.1	0.12+0.0	0.08-0.0	0.12-0.0	0.160.0	0.15
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is DAMORA THERAPEUT profitable?

No, DAMORA THERAPEUT (DMRA) reported a net income of -$209.8M in fiscal year 2025.

What is DAMORA THERAPEUT's EBITDA?

DAMORA THERAPEUT (DMRA) had EBITDA of -$210.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is DAMORA THERAPEUT's return on equity (ROE)?

DAMORA THERAPEUT (DMRA) has a return on equity of -87.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is DAMORA THERAPEUT's operating cash flow?

DAMORA THERAPEUT (DMRA) generated -$6.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are DAMORA THERAPEUT's total assets?

DAMORA THERAPEUT (DMRA) had $260.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does DAMORA THERAPEUT spend on research and development?

DAMORA THERAPEUT (DMRA) invested $26.9M in research and development during fiscal year 2025.

How many shares does DAMORA THERAPEUT have outstanding?

DAMORA THERAPEUT (DMRA) had 2M shares outstanding as of fiscal year 2025.

What is DAMORA THERAPEUT's current ratio?

DAMORA THERAPEUT (DMRA) had a current ratio of 12.98 as of fiscal year 2025, which is generally considered healthy.

What is DAMORA THERAPEUT's debt-to-equity ratio?

DAMORA THERAPEUT (DMRA) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is DAMORA THERAPEUT's return on assets (ROA)?

DAMORA THERAPEUT (DMRA) had a return on assets of -80.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is DAMORA THERAPEUT's cash runway?

Based on fiscal year 2025 data, DAMORA THERAPEUT (DMRA) had $257.6M in cash against an annual operating cash burn of $6.7M. This gives an estimated cash runway of approximately 460 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is DAMORA THERAPEUT's Piotroski F-Score?

DAMORA THERAPEUT (DMRA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are DAMORA THERAPEUT's earnings high quality?

DAMORA THERAPEUT (DMRA) has an earnings quality ratio of 0.03x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can DAMORA THERAPEUT cover its interest payments?

DAMORA THERAPEUT (DMRA) has an interest coverage ratio of -180.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is DAMORA THERAPEUT?

DAMORA THERAPEUT (DMRA) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.